Prochlorperazine-Induced Hemidystonia Mimicking Stroke

Acute focal neurological symptoms demand rapid assessment because intravenous fibrinolytic treatment for eligible ischemic stroke is highly time-dependent. The report Mimicking Acute Stroke highlights the diagnostic tension created by this urgency. The authors describe a pregnant woman whose sudden unilateral weakness and slurred speech triggered a code stroke response, but whose evolving tongue movements and recent exposure to Prochlorperazine indicated hemidystonia instead.

Study Background and Research Question

Stroke mimics are conditions that reproduce some features of acute stroke without an ischemic cerebrovascular lesion. They matter clinically because treating a mimic as stroke can expose a patient to unnecessary risk, while assuming that an unusual presentation is benign can delay treatment for a genuine stroke. The problem becomes especially consequential when clinicians are considering off-label fibrinolytic therapy during pregnancy, where both maternal and fetal considerations influence risk assessment.

The reference study asks a focused question: can Prochlorperazine-induced dystonia present as unilateral hemiplegia and activate an emergency stroke pathway? Prochlorperazine is a dopamine D2 receptor antagonist used in antiemetic therapy and migraine management. Its pharmacology can also produce extrapyramidal symptoms, including akathisia and dystonia. The report’s clinical premise is not that medication effects should replace stroke evaluation, but that a medication-related movement disorder should remain in the differential diagnosis when the neurological pattern changes during observation.

The case involved a woman at ten weeks of pregnancy who was taking Prochlorperazine for hyperemesis gravidarum. The authors identify the event as the first reported case, to their knowledge, of Prochlorperazine-induced hemidystonia functioning as a stroke mimic. This claim and the clinical chronology are presented in the published case report.

Key Innovation from the Reference Study

The innovation is primarily diagnostic rather than therapeutic. Many stroke-mimic discussions focus on metabolic abnormalities, seizures, migraine, or functional neurological symptoms. This report adds a medication-induced, unilateral dystonic syndrome to the emergency differential and shows how it can initially appear as loss of power rather than obvious involuntary movement.

Several observations made the case informative. First, the neurological presentation evolved while the patient was already in a monitored emergency setting. Second, the appearance of repetitive tongue protrusion and rolling supplied a recognizable extrapyramidal clue. Third, a bedside medication review revealed that Prochlorperazine had been started only one day earlier. Finally, rapid improvement after intravenous diphenhydramine provided a pharmacologically coherent response, while subsequent magnetic resonance imaging showed no acute stroke. The combination of temporal exposure, evolving phenotype, targeted treatment response, and imaging was more persuasive than any single finding alone.

This is an important distinction for clinical reasoning. A dopamine D2 receptor antagonist can cause dystonia, but the presence of a plausible adverse effect does not rule out simultaneous cerebrovascular disease. The report therefore supports parallel reasoning: maintain the stroke pathway until urgent assessment is complete, while actively searching for signs that point toward a reversible drug reaction.

Methods and Experimental Design Insights

The study is a single-patient case report, not a controlled clinical trial. Its method is a detailed reconstruction of emergency presentation, examination, medication exposure, intervention, imaging, recurrence, and follow-up. The patient arrived by ambulance after sudden slurred speech, chest and neck discomfort, paresthesias, and severe left-sided weakness. The emergency department activated its code stroke process, obtained laboratory testing, arranged head computed tomography according to institutional protocol, and involved neurology promptly.

The case offers a useful time-course design. Prochlorperazine was a new medication, and the patient reported four oral 10-mg doses in total, with the last dose taken one hour before the onset of neurological symptoms. While she was being prepared for imaging, the tongue began to protrude and roll repetitively. That observation prompted clinicians to reconsider the presentation as a possible extrapyramidal reaction rather than isolated hemiparesis.

Intravenous diphenhydramine was then administered at 50 mg. The motor symptoms rapidly resolved, although the patient initially reported residual limb weakness. Her subsequent neurological examination was normal, with a National Institutes of Health Stroke Scale score of 0. Magnetic resonance imaging showed no evidence of acute stroke. During overnight observation, a second dystonic episode occurred and again responded to 50 mg of intravenous diphenhydramine. Symptoms resolved by the following day, and later pregnancy follow-up documented an uneventful delivery of a healthy term infant. These case details are reported in the reference publication.

Protocol Parameters

• Medication exposure: The literature case involved Prochlorperazine initiated one day before presentation, four total oral 10-mg doses, and a final dose one hour before symptom onset; these are case-specific observations rather than a universal exposure threshold, as described in the reference study.
• Neurological surveillance: The team documented the initial focal deficits, then repeated examinations when tongue protrusion and rolling emerged. Serial examinations are a practical workflow suggestion derived from the case, not a validated diagnostic protocol.
• Acute intervention: A 50-mg intravenous dose of diphenhydramine was followed by rapid improvement, and the same dose was effective during recurrence. This dose reflects the reported case management and should not be treated as individualized medical advice.
• Imaging strategy: Head computed tomography was ordered under the institutional stroke pathway, followed by magnetic resonance imaging, which showed no acute infarction. The case supports completing urgent stroke assessment rather than using suspected dystonia to bypass imaging.
• Medication reconciliation: Asking specifically about recently started dopamine-blocking medicines was central to the diagnosis. In practice, the timing, dose, route, and indication should be recorded alongside the neurological examination.

Core Findings and Why They Matter

The central finding was rapid and reproducible improvement of the abnormal motor syndrome after diphenhydramine, combined with negative magnetic resonance imaging and complete clinical recovery. The recurrence during observation, followed by a second response to the same intervention, strengthened the interpretation of a drug-induced dystonic reaction. The patient experienced no reported long-term neurological sequelae.

For emergency clinicians, the most transferable signal is the mismatch between apparent weakness and later-emerging abnormal movements. Hemidystonia may produce sustained or repetitive contractions that limit voluntary movement and distort speech, creating the outward appearance of hemiplegia. A medication history can therefore be as important as an isolated neurological sign, particularly when a dopamine-blocking antiemetic was recently started.

The case also demonstrates the value of bedside pattern recognition without promoting premature closure. The patient initially required a full stroke response because her symptoms were abrupt and focal. Only after the tongue movements appeared did the team expand the differential. This sequence is clinically defensible: a suspected stroke mimic should be investigated while stroke remains a live possibility.

Comparison with Existing Internal Articles

The internal article Prochlorperazine-Induced Hemidystonia Mimicking Stroke provides a concise practical summary of the same reference case. Its diagnostic warning aligns with the primary report: review medication timing, recognize evolving extrapyramidal signs, assess the response to diphenhydramine, and retain neuroimaging in the evaluation. The primary publication adds the full clinical sequence, including the prehospital stroke activation, laboratory evaluation, magnetic resonance imaging, recurrence during observation, and pregnancy outcome. Thus, the internal summary is useful for rapid orientation, whereas the DOI-linked article should anchor citation and interpretation.

A separate internal overview, Prochlorperazine: A Molecular Bridge in Cancer and Antiviral Research, addresses preclinical applications outside emergency medicine. That scope is complementary but should not be used to infer that the stroke-mimic case demonstrates anticancer or antiviral efficacy.

Why this cross-domain matters, maturity, and limitations

Keeping these domains separate is important for evidence interpretation. The reference report supports a safety and diagnostic observation in acute care; it does not establish an effect in melanoma research, tamoxifen-resistant breast cancer research, or broader cancer research. Likewise, a clinical adverse-effect report cannot validate Prochlorperazine as an in vitro anticancer agent or as an antiviral agent blocking clathrin-mediated endocytosis. Those questions require their own cell-based, mechanistic, and translational evidence.

The maturity of the evidence is therefore uneven. The hemidystonia finding is clinically plausible and supported by a strong temporal pattern, targeted response, recurrence, and imaging, but it remains a rare-event signal from one patient. Preclinical findings from other fields may be mechanistically interesting, yet they should not be merged with the emergency-medicine conclusion without direct comparative studies. This boundary prevents search-driven associations from becoming unsupported clinical claims.

Limitations and Transferability

The principal limitation is the single-case design. There was no comparator group, no standardized incidence estimate, and no systematic assessment of alternative stroke mimics. The absence of an acute lesion on magnetic resonance imaging supports the authors’ interpretation but does not independently prove that Prochlorperazine caused every symptom. A formal drug-causality assessment was not reported, and the patient was not rechallenged with Prochlorperazine, appropriately avoiding deliberate re-exposure to a suspected adverse-effect trigger.

Diphenhydramine response is also supportive rather than pathognomonic. Symptoms may improve over time, and residual subjective weakness initially persisted despite normalization of the examination. This detail cautions against using immediate patient-reported recovery as the sole endpoint. Objective serial examinations, imaging, and observation were all important in the case.

Transferability is strongest for diagnostic workflow. Clinicians evaluating sudden focal deficits should ask about newly initiated dopamine antagonists and inspect for abnormal ocular, facial, lingual, cervical, or limb posturing while continuing appropriate stroke assessment. Transferability is weaker for estimating risk in other patients, including those with different ages, doses, routes of administration, comorbidities, or pregnancy status. The report should inform vigilance, not replace institutional stroke protocols or individualized medical judgment.

Research Support Resources

For laboratory researchers examining receptor-linked pharmacology or cellular responses, Prochlorperazine (SKU A8508) can support similar research workflows. The product information should be consulted for preparation, solvent compatibility, storage, and laboratory safety; research concentrations and handling conditions should not be extrapolated to clinical dosing.